Today's Trend
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is getting mixed attention from analysts after a recent earnings beat and strong Rezdiffra sales growth, but a cluster of updated HC Wainwright forecasts may be weighing on sentiment. The stock has been higher overall, likely helped by the company’s strong Q1 results, but investors are also reacting to lower near-term earnings estimates.
- HC Wainwright kept a Buy rating and $620 price target on Madrigal Pharmaceuticals while raising its FY2028 EPS estimate to $35.23, suggesting confidence in longer-term earnings power.
- Recent coverage highlighted strong Q1 2026 earnings and Rezdiffra sales growth, which supports the case that Madrigal’s commercial momentum remains intact. Article: A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Strong Q1 2026 Earnings And Rezdiffra Sales Growth
- Analysts adjusted several forecasts around the same time, creating a mixed picture for 2026 and beyond.
- HC Wainwright cut its Q2 2026 EPS estimate to ($3.01) from ($0.89), signaling expectations for deeper near-term losses.
- The firm also lowered its Q3 2026 EPS estimate to ($1.05) from ($0.40) and trimmed FY2026 EPS to ($7.07) from ($3.11), which could pressure the stock if investors focus on profitability timing.
- HC Wainwright reduced its FY2027 EPS estimate to $11.78 from $13.25, suggesting a slightly slower earnings ramp than previously expected.
Bottom line: MDGL’s recent strength appears tied to solid quarterly execution and optimism around Rezdiffra, but the stock may be facing some headwinds from lowered near-term earnings expectations even as long-term forecasts remain upbeat.